TNSN04234A1 - N-ACYLAMINOBENZENE DERIVATIVES AS SELECTIVE INHIBITORS OF MONOAMINE OXIDASE B - Google Patents

N-ACYLAMINOBENZENE DERIVATIVES AS SELECTIVE INHIBITORS OF MONOAMINE OXIDASE B

Info

Publication number
TNSN04234A1
TNSN04234A1 TNP2004000234A TNSN04234A TNSN04234A1 TN SN04234 A1 TNSN04234 A1 TN SN04234A1 TN P2004000234 A TNP2004000234 A TN P2004000234A TN SN04234 A TNSN04234 A TN SN04234A TN SN04234 A1 TNSN04234 A1 TN SN04234A1
Authority
TN
Tunisia
Prior art keywords
alkyl
hydrogen
alkoxy
halogen
derivatives
Prior art date
Application number
TNP2004000234A
Other languages
French (fr)
Inventor
Synese Olidon
Sarmiento Rosa Maria Rodriguez
Andrew William Thomas
Rene Wyler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of TNSN04234A1 publication Critical patent/TNSN04234A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/12—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • C07C233/15—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/30—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
    • C07C233/33—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/60—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/16—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/10—Hydrazines
    • C07C243/12—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms
    • C07C243/14—Hydrazines having nitrogen atoms of hydrazine groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
    • C07C243/26—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C243/28—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/19—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same saturated acyclic carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/23—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same unsaturated acyclic carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • C07C255/25—Aminoacetonitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C07C323/41—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne des dérivés de N-acylamino aryle de la formule générale (I); dans laquelle R1 représente halogène-(C1-C6)-alkyle; cyano; C1-C6-alcoxy ou halogène-(C1-C6)-alcoxy; R21; R22; R23 et R24 sont sélectionnés indépendamment les uns des autres dans le groupe formé d'hydrogène; de (C1-C6)-alkyle; d'halogène; d'halogène-(C1-C6)-alkyle; d'hydroxy; de C1-C6-alcoxy ou de CHO; R3 représente hydrogène ou C1-C3-alkyle; R4; R5 sont sélectionnés indépendamment l'un de l'autre dans le groupe formé d'hydrogène; de C1-C6-alkyle; de C1-C6-alcoxy ou de COO(C1-C6)alkyle; ou R4 et R5 forment ensemble avec l'atome C- auquel ils sont liés un noyau C3-C7-cycloalkyle; R6 représente CO-NR7R8; -COO(C1-C6)-alkyle; -CN; -NR2 ou NHC(O)R; R7 et R8 sont sélectionnés indépendamment l'un de l'autre dans le groupe formé d'hydrogène; de C1-C6-alkyle; de NH2 ou d'hydroxy; R représente hydrogène ou C1-C6-alkyle; n est un nombre représentant 0;1; 2 ou 3. X représente CHRO; -OCHR; -CH2S-; -SCH2-; -CH2CH2-; -CH=CH- ou C=C-. Elle concerne également des sels d'addition d'acide pharmaceutiquement actifs de ces dérivés. Ces composés de la formule générale (I) sont des inhibiteurs de la monoamine oxydase B sélectifs et sont par conséquent utiles dans le traitement de maladies liées aux inhibiteurs de la monoamine oxydase B; par exemple dans le traitement de la maladie d'Alzheimer ou de la démence sénile.The invention relates to N-acylamino aryl derivatives of the general formula (I); wherein R1 represents halogen- (C1-C6) -alkyl; cyano; C1-C6-alkoxy or halogen- (C1-C6) -alkoxy; R21; R22; R23 and R24 are independently selected from the group consisting of hydrogen; (C1-C6) -alkyl; halogen; and halogen- (C1-C6) -alkyl; hydroxy; C1-C6-alkoxy or CHO; R3 represents hydrogen or C1-C3-alkyl; R4; R5 are independently selected from each other in the group consisting of hydrogen; C1-C6-alkyl; C1-C6-alkoxy or COO (C1-C6) alkyl; or R4 and R5 together with the C- atom to which they are attached form a C3-C7-cycloalkyl ring; R6 is CO-NR7R8; -COO (C1-C6) -alkyl; CN; -NR2 or NHC (O) R; R7 and R8 are independently selected from the group consisting of hydrogen; C1-C6-alkyl; NH2 or hydroxy; R is hydrogen or C1-C6-alkyl; n is a number representing 0; 1; 2 or 3. X represents CHRO; -OCHR; 2 S-; -SCH2-; -CH2CH2-; -CH = CH- or C = C-. It also relates to pharmaceutically active acid addition salts of these derivatives. These compounds of the general formula (I) are selective monoamine oxidase B inhibitors and are therefore useful in the treatment of diseases related to monoamine oxidase B inhibitors; for example in the treatment of Alzheimer's disease or senile dementia.

TNP2004000234A 2002-05-29 2004-11-24 N-ACYLAMINOBENZENE DERIVATIVES AS SELECTIVE INHIBITORS OF MONOAMINE OXIDASE B TNSN04234A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02011639 2002-05-29
PCT/EP2003/005297 WO2003099763A1 (en) 2002-05-29 2003-05-20 N-acylaminobenzene dervatives as selective monoamine oxidase b inhibitors

Publications (1)

Publication Number Publication Date
TNSN04234A1 true TNSN04234A1 (en) 2007-03-12

Family

ID=29558293

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2004000234A TNSN04234A1 (en) 2002-05-29 2004-11-24 N-ACYLAMINOBENZENE DERIVATIVES AS SELECTIVE INHIBITORS OF MONOAMINE OXIDASE B

Country Status (36)

Country Link
US (3) US6762320B2 (en)
EP (1) EP1511718B1 (en)
JP (1) JP4223003B2 (en)
KR (1) KR100706739B1 (en)
CN (1) CN100482638C (en)
AR (1) AR040133A1 (en)
AT (1) ATE430726T1 (en)
AU (1) AU2003240681B2 (en)
BR (1) BR0311338A (en)
CA (1) CA2486380C (en)
CY (1) CY1109220T1 (en)
DE (1) DE60327522D1 (en)
DK (1) DK1511718T3 (en)
EA (1) EA009372B1 (en)
ES (1) ES2324214T3 (en)
GT (1) GT200300119A (en)
HK (1) HK1081529A1 (en)
HR (1) HRP20041087B1 (en)
IL (1) IL165055A0 (en)
MA (1) MA27208A1 (en)
MX (1) MXPA04011594A (en)
MY (1) MY139027A (en)
NO (1) NO329387B1 (en)
NZ (1) NZ536538A (en)
PA (1) PA8574401A1 (en)
PE (1) PE20040520A1 (en)
PL (1) PL212708B1 (en)
PT (1) PT1511718E (en)
RS (1) RS51642B (en)
SI (1) SI1511718T1 (en)
TN (1) TNSN04234A1 (en)
TW (2) TWI331917B (en)
UA (1) UA79284C2 (en)
UY (1) UY27825A1 (en)
WO (1) WO2003099763A1 (en)
ZA (1) ZA200408965B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009372B1 (en) * 2002-05-29 2007-12-28 Ф. Хоффманн-Ля Рош Аг N-acylaminobenzene derivatives as selective monoamine oxidase b inhibitors
CA2527861A1 (en) * 2003-07-21 2005-02-10 Applied Research Systems Ars Holding N.V. Alkynyl aryl carboxamides
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
CN100441188C (en) * 2003-10-23 2008-12-10 弗·哈夫曼-拉罗切有限公司 Benzazepine derivatives as MAO-B inhibitors
EP1588704A1 (en) * 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
UA89503C2 (en) * 2004-09-13 2010-02-10 Х. Луннбек А/С Substituted aniline derivatives
US7211573B2 (en) * 2004-12-08 2007-05-01 Hoffmann-La Roche Inc. Malonamide derivatives
WO2006089674A2 (en) 2005-02-25 2006-08-31 F.Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
WO2007008963A1 (en) * 2005-07-13 2007-01-18 Jenrin Discovery Mao-b inhibitors useful for treating obesity
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
WO2010008894A1 (en) * 2008-06-24 2010-01-21 Valeant Pharmaceuticals International Benzyloxy anilide derivatives useful as potassium channel modulators
US9006371B1 (en) * 2010-09-28 2015-04-14 United States Of America As Represented By The Secretary Of The Navy Synthesis of oligomeric silsesquioxane monomers for high performance polymers
IT1404729B1 (en) * 2011-01-27 2013-11-29 Univ Pisa HIGHLY SELECTIVE INHIBITORS OF ADAMS ACTIVITY
JP2014512337A (en) * 2011-01-28 2014-05-22 ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション Stilbene analogs and methods of treating cancer
CN105237567B (en) * 2015-11-09 2017-09-29 河北工业大学 A kind of preparation method containing fragrant methyl phosphonate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1003753B (en) * 1953-11-07 1957-03-07 Dr Karl Kindler Process for the preparation of N-dialkylaminoacylaminophenol ethers
JPH05262718A (en) * 1992-03-23 1993-10-12 Taisho Pharmaceut Co Ltd 5-substituted amino-2-phenoxysulfonamide compound
GB9313365D0 (en) * 1993-06-29 1993-08-11 Roussel Lab Ltd Chemical compounds
US5679715A (en) 1995-06-07 1997-10-21 Harris; Richard Y. Method for treating multiple sclerosis
WO1997033572A1 (en) 1996-03-15 1997-09-18 Somerset Pharmaceuticals, Inc. Method for preventing and treating peripheral neurophathy by administering selegiline
WO2001034172A2 (en) 1999-11-05 2001-05-17 Vela Pharmaceuticals Inc. Methods and compositions for treating reward deficiency syndrome
EA009372B1 (en) * 2002-05-29 2007-12-28 Ф. Хоффманн-Ля Рош Аг N-acylaminobenzene derivatives as selective monoamine oxidase b inhibitors

Also Published As

Publication number Publication date
AU2003240681A1 (en) 2003-12-12
US20030232883A1 (en) 2003-12-18
EA200401519A1 (en) 2005-06-30
ZA200408965B (en) 2006-06-28
PE20040520A1 (en) 2004-08-24
CA2486380A1 (en) 2003-12-04
NZ536538A (en) 2007-08-31
RS51642B (en) 2011-10-31
PT1511718E (en) 2009-06-12
TWI331917B (en) 2010-10-21
UY27825A1 (en) 2003-12-31
NO329387B1 (en) 2010-10-11
DE60327522D1 (en) 2009-06-18
JP4223003B2 (en) 2009-02-12
BR0311338A (en) 2005-03-22
ATE430726T1 (en) 2009-05-15
CN100482638C (en) 2009-04-29
US20050283019A1 (en) 2005-12-22
IL165055A0 (en) 2005-12-18
DK1511718T3 (en) 2009-06-22
MXPA04011594A (en) 2005-03-07
GT200300119A (en) 2004-03-15
TWI340641B (en) 2011-04-21
WO2003099763A1 (en) 2003-12-04
PL375311A1 (en) 2005-11-28
RS101204A (en) 2007-02-05
SI1511718T1 (en) 2009-08-31
US7053245B2 (en) 2006-05-30
TW201036607A (en) 2010-10-16
MY139027A (en) 2009-08-28
JP2005527617A (en) 2005-09-15
KR20050016460A (en) 2005-02-21
HK1081529A1 (en) 2006-05-19
WO2003099763A8 (en) 2004-03-18
KR100706739B1 (en) 2007-04-11
PA8574401A1 (en) 2003-12-19
CN1656057A (en) 2005-08-17
ES2324214T3 (en) 2009-08-03
US20040210079A1 (en) 2004-10-21
HRP20041087B1 (en) 2013-06-30
EP1511718A1 (en) 2005-03-09
TW200401632A (en) 2004-02-01
AR040133A1 (en) 2005-03-16
NO20044806L (en) 2004-12-29
EP1511718B1 (en) 2009-05-06
EA009372B1 (en) 2007-12-28
CY1109220T1 (en) 2014-07-02
CA2486380C (en) 2011-10-25
HRP20041087A2 (en) 2005-06-30
MA27208A1 (en) 2005-01-03
UA79284C2 (en) 2007-06-11
AU2003240681B2 (en) 2008-10-09
PL212708B1 (en) 2012-11-30
US6762320B2 (en) 2004-07-13

Similar Documents

Publication Publication Date Title
TNSN04234A1 (en) N-ACYLAMINOBENZENE DERIVATIVES AS SELECTIVE INHIBITORS OF MONOAMINE OXIDASE B
TNSN07041A1 (en) N- (1H-INDOLYL) -I H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
MA28271A1 (en) Benzenesulfonylamino-pyridine-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-HSD-1) for the treatment of diabetes and obesity
MA32088B1 (en) Bicyclic derivatives of azabicyclic carboxamides, their preparation and their therapeutic application
CA2662848C (en) 2-aryl-6-phenylimidazo[1,2-.alpha.]pyridine derivatives, preparation thereof and therapeutic use thereof
MA29807B1 (en) Phenyl- [1,2,4] -oxadiazol-5-one derivatives with a phenyl group, processes for their preparation and their use as pharmaceuticals.
TNSN04156A1 (en) SUBSTITUTED PYRIDINONES AS MODULATORS OF MAP-KINASE P38
MA25035A1 (en) NEW 3-AZABICYCLO [3,1,0] HEXANE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM
MA27079A1 (en) DERIVATIVES 1, 6-NAPHTHYRIDINE AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED DISORDERS
MA28147A1 (en) PYRAZOLE DERIVATIVES AS MEDICAMENTS FOR THE TREATMENT OF ACUTE OR CHRONIC NEURONAL DEGENERATION
CA2397636A1 (en) Dihydro-1,3,5-triazine amine derivatives and their therapeutic uses
US20080249181A1 (en) Compositions Having Antimycrobial Activity Including a Hydroxamate or a Hydroxamate and a Hydroxlyamine
JPH05507929A (en) Ether lipid-nucleoside covalent conjugate
CA2633057A1 (en) Fgf-peceptor agonist dimeric compounds
HUP0105073A2 (en) 2-aminopyridine derivatives, their use as medicines and pharmaceutical compositions containing them
MA30167B1 (en) NEW COMPOUNDS
EP0409939A1 (en) Use of polyunsaturated fatty acid derivatives in the preparation of medicaments with tyrosine kinase inhibiting activity
MA31674B1 (en) Derivatives of 7-alkynil-1,8-naviteredone prepared and therapeutic uses
CA2275345A1 (en) Pro-drugs and counterparts of camptothecin, their application as medicines
MA31629B1 (en) 1-0X0-1,2-DIHYDROISOQUINOLINE-5-CARBOXAMIDE AND 4-OXO-3,4-DIHYDROQUINAZOLINE-8-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
MA27795A1 (en) CYCLIC AMINE DERIVATIVES, PROCESSES FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
MA29793B1 (en) IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS.
JPH06192222A (en) Succinic acid imide derivative
LU87935A1 (en) PROCESS FOR THE PREPARATION OF FURO (3,4-C) PYRIDINE DERIVATIVES IN NON-RACEMIC FORM
EP0437144B1 (en) Non-ionic iodinated compounds, procedure for their preparation and contrast agents containing them